MyCanadian Phramacy


Can anybody suggest a way making registars follow US state law and
ICANN rules regarding falsified registrant data ?

I have to stop spammers using my personal email address for advertising
erection packs and falsified pills by MyCanadian Phramacy.

MyCanadian Phramacy is a sad, year long crime story of ignorant
registrars , provider and incompetent law enforcement agencies:
BBB Issues International Alert: Online Pharmacy Seller Using BBB
Trademarks to Market Drugs

For Immediate Release
[Arlington, VA, July 29, 2005] —

The Better Business Bureau system today issued an alert about online pharmacy sites that are displaying the BBB’s trademarks to market drugs on the Internet.

People from every region of the United States are contacting the BBB to inquire about the legitimacy of a “business” that is targeting consumers through
spamming. The e-mail messages contain claims that the company is
“Verified by the BBB” and include a hyperlink to different web sites
all using the same name MyCanadianPharmacy, Ltd. (not to be confused
with Canada Drugs, Ltd. that owns and The web sites involved in this scam use at least the following addresses:


All of the web sites use the same template, display the BBBOnLine
Reliability Logo and an untrue message claiming to be “Listed at Better Business Bureau.”

This practice misleads consumers and violates United States trademark, counterfeiting and copyright laws.

These sites are in no way affiliated with the Better Business Bureau.
The BBB does not recommend visiting these sites, as there is some
evidence that the sites may try to download software to visitors’
The Council of Better Business Bureaus is unable to identify precisely who is behind these fraudulent Web sites because whoever registered them submitted phony contact information to the registrar. It does appear, however, that most of the spam messages originate from Korea….”

One of’s name server was registered by:
Domain ID:D13445012-LRMS
Created On:17-May-2006 19:01:01 UTC
Last Updated On:25-May-2006 16:15:14 UTC
Expiration Date:17-May-2007 19:01:01 UTC
Sponsoring Registrar:Tucows Inc. (R139-LRMS)

Registrant ID:tuCj0jDed3lPiwgz
Registrant Name:Mike Ounen
Registrant Organization:Teich Andre
Registrant Street1:Rr.Qemal Stafa, 1
Registrant Street2:
Registrant Street3:
Registrant City:Tirane
Registrant State/Province:Tirane
Registrant Postal Code:16040
Registrant Country:AL
Registrant Phone:+355.04230880

Canada must be larger than I thought
What do you receive if you place an order with “My Canadian Pharmacy”?
It’s anybody’s guess. You might receive a generic equivalent drug, but because most of the drugs these folks advertise have no generic
equivalents you’ll probably receive a placebo that’s designed to look like the medication you ordered.

If you’re lucky, you’ll receive a placebo that’s in a counterfeit
package. But you might also receive a forged medication that’s stronger or weaker than the real product. Or you might receive something that’s truly dangerous. If you’re taking the medication for something serious, any deviation from the real thing would be dangerous.
The site says “Dr. Jack Poppins studied reanimatology at Ontario
Medical State University in 1969.” Perform a Google search for “Ontario Medical State University” and you’ll find exactly 2 references: Both are on the MyCanadianPharmacy website. What the writer seemed not to know is that Canada has provinces, not states.

The site also says “Dr. Paul Newman graduated from the faculty of
psychiatry of the University of Ottawa.” Better guess this time. The
University of Ottawa exists and even has a medical school…”…so_id=3DROK6271
After contacting the dns service provider(, thanks), Phramacy) switched their dns servers within
minutes from[vbcol=seagreen]
authority: 172800 NS
authority: 172800 NS
authority: 172800 NS
authority: 172800 NS….a25c3caee05874=

It appears there is No way to get them nailed down by dns providers if they have hundreds of spare dns domains to switch. The only way seems to get them is by their name registrars.

A proof about false registrant data was sent to ITSYOURDOMAIN.COM,
registrar of

Michal Kralik
Kralik Michal
1121 Old Fm 440 Rd
Killeen, TX 76549 US

Michal Kralik
Kralik Michal
1121 Old Fm 440 Rd
Killeen, TX 76549 US

The person owning this phone number is not Michal Kralik and has
nothing to do with
The US White Pages do not list a ‘Michal Kralik’ in Tx or vicinity.
The company address given on (MyCanadianPharmacy) is
false. There is no valid phone number given on their web page.

They simply came back:
“=2E.please note we do not do any web-hosting and you should contact the company hosting this site. Thanks!

Customer Support
supp… ”

A decent reminder about US state law and ICANN rules was answered by
A phone discussion with an official lady confirmed my impresssion:
They simply will ask the registrant to update their data.

”In the event Registrar learns of inaccurate contact information
associated with a Registered Name it sponsors, it shall take reasonable steps to correct that inaccuracy…The term “reasonable steps” is not defined within the agreement; precisely what constitutes reasonable steps to investigate and correct a reported inaccuracy will vary depending on the circumstances (e.g., accepting unverified “corrected” data from a registrant that has already deliberately provided incorrect data may not be appropriate). “(Registrar Advisory Concerning Whois Data Accuracy)

Upon this subject, the official ended the

One thought on “MyCanadian Phramacy

  1. SFA Reporter says:
    Canadadrugs 9/21/12 Department of Health and Human Services logoDepartment of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993-0002 TO: FROM: Food and Drug Administration Internet Pharmacy Task Force RE: Internet Marketing of Unapproved and Misbranded Drugs DATE: September 21, 2012 WARNING LETTER This revised warning letter supersedes the warning letter sent to you on September 18, 2012. The warning letter sent to you on September 18, 2012, is withdrawn. The United States Food and Drug Administration (FDA) recently reviewed your websites (listed in the table located at the bottom of this letter and in the attachment) and has determined that your websites offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved and misbranded new drugs for sale in violation of sections 301(a), 301(d), 502(a), 502(f), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 352(a), 352(f), 355(a)]. We request that you immediately cease marketing violative drug products to United States consumers. Unapproved New Drugs Certain products you offer for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act [21 U.S.C. §§ 355(a) and 331(d)]. As a few examples, your firm offers for sale through your websites products such as “Viagra” and “Levitra,” which are the proprietary names of FDA-approved drugs well-known for their intended use(s) to treat disease, and as such are subject to section 505 of the FD&C Act [21 U.S.C. § 355]. However, your websites offer “Viagra” and “Levitra” that are manufactured by manufacturers that are not the subject of the FDA-approved applications, and accordingly, no approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for the products your firm offers for sale. The drugs your firm offers for sale without approved applications are in violation of section 505 of the FD&C Act [21 U.S.C. § 355]. In addition to the above-mentioned drug products offered for sale through your websites, your firm offers unapproved and misbranded domperidone. In 2004, amid safety concerns, FDA issued a consumer alert for breastfeeding women warning against the use of domperidone for increased milk production. Such reported safety concerns included cardiac arrhythmias, cardiac arrest, and sudden death. FDA concurrently issued warning letters to pharmacies that were compounding products containing Domperidone and to firms that supplied domperidone for use in compounding. Domperidone is not approved for any human use in the U.S., and it is currently subject to an import alert (61-07) instructing FDA personnel to detain and refuse entry of any shipments of this drug offered for importation to the US. Misbranded Drugs Because the above mentioned drugs are intended for conditions that are not amenable to self-diagnosisand treatment by individuals who are not medical practitioners, adequate directions cannot be written for them so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses, causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because some of your products lack required approved applications, they are not exempt under 21 C.F.R. § 201.115 from the requirements of section 502(f)(1) of the FD&C Act. Furthermore, your websites offer unapproved Accutane (isotretinoin) for sale. FDA approved the new drug application (NDA) for Accutane in 1982, but withdrew the approval via a Federal Register Notice effective November 22, 2010. The Accutane product offered for sale on your websites is unapproved within the meaning of section 505(a) of the FD&C Act [21 U.S.C. § 355(a)] in that this is a new drug without an approved application. The introduction or delivery for introduction into interstate commerce of unapproved drug products violates section 301 of the FD&C Act [21 U.S.C. § 331]. Moreover, your websites offer for sale misbranded drugs containing isotretinoin. Although isotertinoin is legally marketed under approved abbreviated new drug applications (ANDAs), FDA-approved drugs containing isotretinoin are available in the United States only under specially created safety controls. If these products are not taken under the close supervision of a healthcare professional and pharmacist, they can be a potentially dangerous prescription drug. Because isotretinoin has serious risks, patients, their doctors and pharmacists are required by FDA to register with the iPLEDGE program in order to receive this medication, among other requirements. These safety controls are bypassed when this drug is purchased from foreign sources or over the Internet, placing patients who use this drug at risk. To offer isotretinoin for sale without the above-mentioned safety controls misbrands the product as it is false and misleading to the consumer and adequate warnings against use are not provided per sections 502(a) of the FD&C Act [21 U.S.C. § 352(a)] and 502(f)(2) of the FD&C Act [21 U.S.C. § 352(f)(2)], respectively. FDA is taking this action against your firm because of the inherent risk in buying unapproved and misbranded new drugs. Unapproved new drugs from unregulated sources do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and such drugs have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice. Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at Table of Websites: URL Redirect atorvsa, australiaonllnedrl! britain· brltain· britain· britain· britain· – can-drug. net can-drugs. net canada· canada· canada· canada-prescription. net Canada- canadadru& – canada& — canadian· canadian· canadia- can can cdn· drug-depot. net exportdruamart.c0m – export & globed rugs. net india· medical-drugs. com med medicationscanada.inf mydru&

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.